Radiopharmaceuticals can use the same molecular scaffold for diagnosing a tumor with one radionuclide and treating it with another. This "theranostic" strategy improves patient stratification and accelerates the transition from diagnosis to effective therapy.

Major advancements in biotech instrumentation are not just software or AI achievements. They are the result of a deeply multidisciplinary effort over many years, requiring innovations and integration across optics, fluidics, chemistry, hardware, and biology to create powerful new tools.

Histosonics is pioneering the next stage of surgery by using focused sound waves to non-invasively liquefy tumors. This breakthrough technology can treat patients previously deemed non-surgical candidates, improving their condition enough to make them eligible for surgical resection or even organ transplants, creating entirely new therapeutic pathways.

Major innovation doesn't always require inventing something new. Medtronic proved a 20-year-old therapy, Onyx, could treat a new condition, demonstrating that finding novel applications for existing, proven technologies can be a powerful and efficient R&D strategy.

The technology behind Midjourney's new medical scanner has roots in David Holz's first company, Leap Motion. The expertise in sensing, detecting, and mapping developed for hand-tracking in VR provided the technical foundation for the much more ambitious full-body ultrasonic scanner, showing how past ventures seed future breakthroughs.

Individual early-detection tests like blood biopsies or MRIs are imperfect, leading to false positives and negatives. The next step in diagnostics is a "multimodal" approach, layering different screening types, such as genomic blood tests and imaging, to create a more accurate and comprehensive picture of a patient's health.

The next wave of MedTech innovation won't just come from engineers. It will come from creating tools that allow surgeons and clinicians—those who see problems firsthand—to easily prototype and de-risk new device concepts, vastly expanding the market for innovation itself.

The next leap in medicine isn't just delivering a payload but programming it with conditional logic. Radar Therapeutics engineers mRNA to act like software with "if/and/or" commands. This allows the therapy to sense its cellular environment and activate only in the right context, moving beyond a simple "execute" function.

The combination of diagnostics and therapeutics into a single "theragnostic" agent is a key breakthrough. This approach allows for better patient stratification and offers new hope for cancers like pancreatic ductal adenocarcinoma (PDAC), which have dismal survival rates.